PersonalisPSNL
PSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 229
0
Funds holding %
of 7,321 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 26
14% more call options, than puts
Call options by funds: $462K | Put options by funds: $404K
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
3% less funds holding
Funds holding: 107 [Q4 2024] → 104 (-3) [Q1 2025]
10.55% less ownership
Funds ownership: 72.67% [Q4 2024] → 62.12% (-10.55%) [Q1 2025]
35% less capital invested
Capital invested by funds: $298M [Q4 2024] → $192M (-$106M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
47%
upside
Avg. target
$9
47%
upside
High target
$9
47%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 47%upside $9 | Buy Maintained | 7 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung an.
Positive
Zacks Investment Research
2 weeks ago
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Positive
Zacks Investment Research
1 month ago
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Business Wire
1 month ago
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results.
Neutral
Business Wire
1 month ago
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer. “Many triple negative.
Neutral
Business Wire
1 month ago
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. “These studies continue to expand the clinical data for NeXT Personal into new areas, in.
Neutral
Business Wire
2 months ago
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guid.
Neutral
Seeking Alpha
2 months ago
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital William Bonello - Craig-Hallum Vidyun Bais - BTIG Daniel Brennan - Cowen Yuko Oku - Morgan Stanley Swayampakula Ramakanth - H.C. Wainwright Operator Greetings.
Negative
Zacks Investment Research
2 months ago
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago.
Neutral
Business Wire
2 months ago
Personalis Reports First Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted c.
Charts implemented using Lightweight Charts™